Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results

• Published in: Ophthalmology (Rochester, Minn.) Vol. 122; no. 11; pp. 2351 - 2359
• Main Authors: Tomkins-Netzer, Oren, Lightman, Susan, Drye, Lea, Kempen, John, Holland, Gary N, Rao, Narsing A, Stawell, Richard J, Vitale, Albert, Jabs, Douglas A
• Format: Journal Article
• Language: English
• Published: United States 01-11-2015
• Subjects: Administration, Oral; Adult; Aged; Drug Implants; Female; Fluocinolone Acetonide - administration & dosage; Fluorescein Angiography; Follow-Up Studies; Glucocorticoids - administration & dosage; Humans; Intravitreal Injections; Macular Edema - diagnosis; Macular Edema - drug therapy; Macular Edema - etiology; Male; Middle Aged; Prednisolone - administration & dosage; Prospective Studies; Tomography, Optical Coherence; Treatment Outcome; Uveitis - complications; Uveitis - diagnosis; Uveitis - drug therapy; Visual Acuity - drug effects
• ISSN: 0161-6420; 1549-4713
• DOI: 10.1016/j.ophtha.2015.07.036

To evaluate the 2-year outcomes of uveitic macular edema.
Longitudinal follow-up of a randomized cohort.
At baseline, 148 eyes of 117 patients enrolled in the Multicenter Uveitis Steroid Treatment (MUST) Trial had macular edema, and 134 eyes of 108 patients completed 2-year follow-up.
Patients enrolled in the study were randomized to either systemic immunosuppression or intravitreal fluocinolone acetonide implant therapy. Macular edema was defined as thickening of the retina (center point thickness≥240 μm) on time-domain optical coherence tomography (OCT) of macula.
Improvement in macular edema (≥20% reduction in central point thickness on OCT), resolution of macular edema (normalization of thickness on OCT), and best-corrected visual acuity (BCVA).
Between randomization and 2-years' follow-up, 62% and 25% of eyes in the systemic and implant groups, respectively, received at least 1 supplemental regional corticosteroid injection. By 2-years' follow-up, macular edema improved in 71% of eyes and resolved in 60%. There were no differences between treatment groups in the proportion of eyes with macular edema improving (systemic therapy vs. implant, 65% vs. 77%; P=0.20) and resolving (52% vs. 68%; P=0.28), but eyes randomized to implant had more improvement in macular thickness (median decrease of 180 vs. 109 μm in the systemic therapy group; P=0.04). Eyes with baseline fluorescein angiographic leakage were more likely to improve than those without (76% vs. 58%; P=0.03). Overall, there was a mean 5-letter (1 line) improvement in BCVA at 2 years. Mean changes in BCVA from baseline at 2 years by macular edema response status were: resolution, +10 letters; improvement without resolution, +10 letters (P=0.92); little to no change, 6 letters (P=0.19); and worsening, -16 letters (worsening acuity; P=0.0003).
About two thirds of eyes with uveitic macular edema were observed to experience improvement in the edema and visual acuity with implant or systemic treatment. Fluocinolone acetonide implant therapy was associated with a greater quantitative improvement in thickness. Fluorescein angiography leakage was associated with a greater likelihood of improvement in macular edema.